低强度脉冲超声波治疗勃起功能障碍的治疗方法
Shi-Yun Liu1, Si-Yu Liu, Bang-Min Han
1Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Asian journal of andrology
|June 3, 2025
概括
低强度脉冲超声波 (LIPUS) 疗法为勃起功能障碍提供了非侵入性治疗,改善组织修复和功能. 进一步的研究将优化LIPUS参数,以改善临床结果.
科学领域:
- 生物医学工程 生物医学工程
- 再生医学是一种再生医学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 低强度脉冲超声波 (LIPUS) 是FDA批准的一种非侵入性声动疗法.
- 临床研究表明,LIPUS有效地治疗轻度至中度勃起功能障碍 (ED),没有不良事件.
研究的目的:
- 研究LIPUS在治疗勃起功能障碍方面的治疗机制.
- 探索LIPUS如何促进洞穴组织的修复和康复.
主要方法:
- 洞穴体的组织学分析.
- 研究非热性LIPUS机制 (腔化,声流,质量转移,机械刺激).
- 机械生物转导通路的分析.
主要成果:
- 利普斯可以缓解纤维化,增强新血管化,并促进洞穴组织的内化.
- 非热效应刺激细胞增殖,血管新生,ECM重塑和干细胞分化.
- 利普斯通过机械生物转导促进洞穴组织的修复.
结论:
- 通过洞穴性康复,LIPUS显示出治疗勃起功能障碍的巨大潜力.
- 需要进一步的研究,以充分阐明LIPUS介导的细胞调节和优化治疗参数.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
571
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
571
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
466
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
466